Please ensure Javascript is enabled for purposes of website accessibility

Eli Lilly to Participate in Program to Make Insulin Cheaper for Seniors

By Prosper Junior Bakiny - Mar 11, 2020 at 2:13PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugmaker has faced scrutiny and anger over the high prices of its insulin products.

Eli Lilly (LLY 0.15%), one of the largest manufacturers of insulin in the U.S., recently announced its intention to participate in a new "Senior Saving Model" that will reduce insulin prices for seniors enrolled in Medicare Part D.

The Centers for Medicare and Medicaid Services (CMS) will launch the new model on Jan. 1, 2021, and all of Eli Lilly's insulin products will be covered. According to CEO David. A Ricks, this program is expected to have a "significant and positive" impact on seniors. 

Diabetic person measuring her blood glucose level.

Image Source: Getty Images.

A target for lawmakers

Eli Lilly has faced public censure in recent years for its long pattern of  significantly increasing the prices of its insulin products. Last year, the Senate Finance Committee launched an investigation into rising insulin prices. The bipartisan probe took particular issue with Eli Lilly, which between 2001 and 2015 boosted the price of its Humalog product from $35 to $234 for a month's supply, a 585% increase.

The committee sent a letter to the company requesting information regarding the insulin products it sells in the U.S. and how it fixes their prices, among other things.  Eli Lilly wasn't the only company targeted, however. Lawmakers also took Novo Nordisk (NVO 0.19%) and Sanofi (SNY 1.96%) to task -- both manufacture notable shares of the insulin sold in the U.S.

In part in response to this scrutiny, all three pharma giants had previously decided to offer lower-cost versions of some of their insulin products.    Perhaps its participation in this new CMS initiative is yet another way Eli Lilly is looking to appease the wrath of lawmakers, patients, and consumer advocacy groups. But most importantly, as the company itself said, "No one should have to ration insulin when managing their diabetes." 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
$324.71 (0.15%) $0.48
Sanofi Stock Quote
$51.01 (1.96%) $0.98
Novo Nordisk A/S Stock Quote
Novo Nordisk A/S
$111.64 (0.19%) $0.21

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.